共 361 条
[21]
La Rosa A(2013)The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case–control study BMC Infect Dis 13 414-1385
[22]
Kuller LH(2012)Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir AIDS 26 2315-645
[23]
Pett SL(2009)Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment AIDS 23 1547-1122
[24]
Ristola M(2012)Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir AIDS 26 1371-1646
[25]
Ross MJ(2010)Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients PLoS One 5 e13188-790
[26]
Shlipak MG(2013)Systemic effects of inflammation on health during chronic HIV infection Immunity 39 633-733
[27]
Tracy R(2011)Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer J Natl Canc Inst 103 1112-666
[28]
Neaton JD(2011)Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death J Infect Dis 203 1637-153
[29]
Mavigner M(2011)INSIGHT SMART Study Group. Plasma levels of soluble CD14 independently predict mortality in HIV infection J Infect Dis 203 780-1861
[30]
Delobel P(2010)Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy J Infect Dis 202 723-1226